Scarica l'app Stockscreener
1.80
28.57%
0.40
Precedente Chiudi:
$1.40
Aprire:
$1.46
Volume 24 ore:
34.90M
Relative Volume:
8.69
Capitalizzazione di mercato:
$166.91M
Reddito:
-
Utile/perdita netta:
$-69.31M
Rapporto P/E:
-1.4173
EPS:
-1.27
Flusso di cassa netto:
$-62.80M
1 W Prestazione:
-82.73%
1M Prestazione:
-82.00%
6M Prestazione:
-59.09%
1 anno Prestazione:
-61.21%
Intervallo 1D:
$1.45
$1.85
Intervallo di 1 settimana:
$1.07
$11.16
Portata 52W:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Confronta RZLT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
1.80 | 129.82M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-08-27 | Iniziato | Guggenheim | Buy |
| 2024-07-17 | Iniziato | BTIG Research | Buy |
| 2024-06-04 | Iniziato | Craig Hallum | Buy |
| 2024-04-09 | Iniziato | Maxim Group | Buy |
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
Rezolute (NASDAQ:RZLT) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Rezolute (NASDAQ:RZLT) Reaches New 12-Month Low on Analyst Downgrade - MarketBeat
Jefferies Raises Rezolute’s Price Target Amid Promising Drug Prospects - StocksToTrade
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView
Jefferies Lifts Rezolute’s Target amid New Data Anticipation - timothysykes.com
Rezolute stock crashes after sole pipeline candidate fails Phase III - Clinical Trials Arena
Craig-Hallum downgrades Rezolute stock to Hold on failed Phase III trial - Investing.com Australia
Rezolute price target lowered to $4 from $20 at Maxim - TipRanks
Rezolute decimated on Phase III miss for ersodetug - The Pharma Letter
Rezolute stock price target slashed by Guggenheim after trial failure - Investing.com Nigeria
RZLT Maintains Buy Rating despite Guggenheim's Lowered Price Tar - GuruFocus
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts - ts2.tech
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire
Craig-Hallum Downgrades Rezolute to Hold From Buy, Adjusts PT to $2 From $18 - marketscreener.com
Rezolute stock price target slashed by H.C. Wainwright after failed study - Investing.com
Rezolute (RZLT): HC Wainwright & Co. Significantly Lowers Price Target | RZLT Stock News - GuruFocus
HC Wainwright & Co. Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
What analysts say about Rezolute Inc 6HV1 stockProtective Put Strategies & Rapid Portfolio Growth - earlytimes.in
Rezolute, Inc. (NASDAQ:RZLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rezolute fails phase 3 for RZ358 as placebo response masks 10 mg/kg efficacyCHOSUNBIZ - Chosunbiz
Rezolute stock hits 52-week low at 1.21 USD despite strong annual gain - Investing.com Canada
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure - The AI Journal
Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Two Biotechs Crash, One Down 88%, On Failed Insulin Drug - Investor's Business Daily
Rezolute, Inc. (RZLT): The "sunRIZE" Post-Mortem & The Tumor Hyperinsulinism Pivot (NASDAQ:RZLT) - Seeking Alpha
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns - ts2.tech
Rezolute (RZLT): Assessing Valuation After a Year of Strong Share Price Gains - Yahoo Finance
Is RZLT Stock A Hidden Gem? - StocksToTrade
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - The AI Journal
Rezolute, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – RZLT - marketscreener.com
Market movers: Rezolute, Oracle, Planet Labs… - Proactive Investors
Failed Trials And Missed Targets Send Shares Reeling - Finimize
Rezolute (RZLT) Stock: Dips Sharply After Phase 3 SunRIZE Trial Disappoints Investors - parameter.io
Rezolute stock price target cut to $5 from $17 at BTIG after trial failure - Investing.com
RZLT: Phase 3 Sunrise study for ersodetug in congenital HI failed to show significant benefit over placebo - TradingView
Rezolute plunges 90% as Phase 3 sunRIZE trial for low BP fails | Tap to know more | Inshorts - Inshorts
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage - ts2.tech
Rezolute keeps door open for hyperinsulinism drug despite Phase III miss - FirstWord Pharma
Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial - Benzinga
Rezolute’s lone drug misses a phase III - BioWorld MedTech
Rezolute (RZLT) Shares Plummet 89% After Phase 3 Trial Setback - GuruFocus
INVESTOR ALERT: Investigation of Rezolute, Inc. (RZLT) by Holzer & Holzer, LLC - GlobeNewswire
Rezolute (RZLT) Downgraded by Wedbush Following Phase 3 Study Re - GuruFocus
Rezolute Downgraded to Hold Amid Disappointing Phase 3 Trial Results for Ersodetug - TipRanks
Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss - TipRanks
Is Rezolute (RZLT) Using sunRIZE Phase 3 And Shelf Filing To Quietly Recast Its Strategy? - simplywall.st
BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities - GlobeNewswire
Wedbush Downgrades Rezolute to Neutral From Outperform, Price Target is $1 - marketscreener.com
Rezolute (RZLT) Shares Dip Following Phase 3 Trial Setback - GuruFocus
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):